ANDA Renaissance: FDA Aims To Reduce Refuse-To-Receive Actions
This article was originally published in The Pink Sheet Daily
About to start GDUFA negotiations, agency wants to enhance communication with sponsors to avoid returning their applications.
You may also be interested in...
Generic user fees could be segmented further by addition of new group.
Biden administration sets May 11 as end date for public health emergency. CDER has said it will work with sponsors to help them gain approval of COVID therapeutics cleared under emergency use authorizations, but agency will likely not issue a formal transition framework.
OTAT Director Bryan, who has worked at the FDA for more than 20 years, will depart by the end of March as the agency’s cell and gene therapy operations are poised for a major overhaul and a large number of new hires.